Merck's Keytruda Enters Phase 3 Clinical Trial for High-Risk Cervical Cancer with Prior Chemotherapy
Maximizing Treatment Through the Introduction of Prior Chemotherapy
The NRG-GY037 Phase 3 clinical trial, sponsored by the U.S. National Cancer Institute (NCI) and conducted by NRG Oncology, evaluates a new treatment paradigm by adding induction chemotherapy prior to the existing standard treatment. This trial targets patients with newly diagnosed, high-risk, locally advanced cervical cancer. The strategy aims to proactively reduce tumor size and suppress micrometastases before radiation therapy. The control group will receive the standard treatment, which consists of Merck's immune checkpoint inhibitor, pembrolizumab (brand name: Keytruda), and cisplatin-based concurrent chemoradiotherapy (CCRT). The experimental group will undergo a combination regimen, starting with a triple combination of carboplatin, paclitaxel, and pembrolizumab as induction therapy, followed by the standard treatment.
Early Intervention Strategy with Immune Checkpoint Inhibitors
The core of this trial is the early administration of pembrolizumab, which blocks the binding of PD-L1 protein on tumor cells and PD-1 (Programmed Death-1) receptors on T cells. Previously, it was administered concurrently with radiation therapy. However, the purpose is to maximize the systemic anti-cancer effect by introducing the immune checkpoint inhibitor at an earlier stage when the immune system is more activated. Carboplatin, used in conjunction, acts through DNA alkylation to inhibit the proliferation of cancer cells, and paclitaxel stabilizes microtubules to inhibit cell division. These are classic anticancer agents, but they are combined to create synergy with the immune anticancer effect. This triple combination therapy effectively eliminates residual cancer cells, ultimately leading to improved long-term survival rates in patients.
Evolution of Standard Cervical Cancer Treatment and Market Competition
The global cervical cancer treatment market is estimated at approximately $6.9 billion to $9.6 billion in 2026 and is projected to reach up to $14.8 billion by 2034, making it an attractive area. Currently, the market is dominated by Merck, with Keytruda-based KEYNOTE-A18 therapy, which received FDA approval in January 2024, establishing itself as the first-line standard treatment. However, competing treatments, such as Tivdak (active ingredient: tisotumab vedotin), an antibody-drug conjugate (ADC) developed by Genmab and Pfizer, are accelerating their entry into the market. In this situation, Merck aims to expand its dominance into the prior therapy market early on, blocking the paths of competitors and maintaining its market-leading position.
Expectations for Clinical Success and Addressing Unmet Needs
Patients with high-risk, locally advanced cervical cancer have long sought more potent initial treatment options due to rapid lymph node metastasis and high recurrence rates after diagnosis. If this Phase 3 trial is successful and demonstrates significant improvements in progression-free survival (PFS) and overall survival (OS), the standard guidelines will change to incorporate prior therapy from the initial treatment. This will provide patients with an innovative opportunity to increase their chances of cure and will also serve as an opportunity for the medical field to enhance the effectiveness of surgery or radiation therapy. The clinical trial began patient recruitment and first administration in November 2025, and is expected to be completed by December 2030, when the final data is expected to be available, and it is expected to continue to attract attention from the industry and investors.
This NRG-GY037 Phase 3 clinical trial will be a medium- to long-term turning point for Merck's pembrolizumab (Keytruda) in the global cervical cancer market, estimated at up to $9.6 billion in 2026, to expand its territory beyond the first-line standard treatment to the prior therapy stage. Following the approval of the concurrent chemoradiotherapy (CCRT) standard treatment through the KEYNOTE-A18 trial in January 2024, the goal is to proactively redefine the treatment paradigm by adding prior chemotherapy with a triple combination regimen. From the perspective of industry professionals, the key is to maximize the synergy with existing cytotoxic anticancer agents such as paclitaxel and carboplatin to demonstrate data on reducing recurrence rates through the elimination of residual cancer cells. In a situation where competing drugs such as Pfizer's Tivdak are seeking to penetrate the cervical cancer market, this is a strategy to solidify its dominance by securing the initial treatment market. If the trial is successful, with an expected completion date of December 2030, it is analyzed that Merck will achieve both expanded indications and life cycle extension in the face of the patent expiration of Keytruda, resulting in significant financial benefits.
Source: ClinicalTrials.gov (api_ct)